No evidence of an increase in early infant mortality from congenital adrenal hyperplasia in the absence of screening

Archives of Disease in Childhood

Volumn 99, Issue 2, 2014, Pages 158-164

  Hird, Beverly E ^a   Tetlow, Lesley ^a   Tobi, Simon ^a   Patel, Leena ^b   Clayton, Peter E ^c  

^a MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^b ROYAL MANCHESTER CHILDREN S HOSPITAL   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYPROGESTERONE; STEROID 21 MONOOXYGENASE;

ARTICLE; CAUSE OF DEATH; CONGENITAL ADRENAL HYPERPLASIA; CONTROLLED STUDY; DRIED BLOOD SPOT TESTING; FEMALE; GENE MUTATION; GESTATIONAL AGE; HUMAN; INFANT; INFANT MORTALITY; MAJOR CLINICAL STUDY; MALE; NEWBORN; NEWBORN SCREENING; PREMATURITY; PRIORITY JOURNAL; SALT WASTING; STEROID 21 MONOOXYGENASE DEFICIENCY; UNITED KINGDOM;

21-HYDROXYLASE DEFICIENCY; CONGENITAL ADRENAL HYPERPLASIA; INFANT MORTALITY; NEONATAL SCREENING; NEWBORN SCREENING;

17-ALPHA-HYDROXYPROGESTERONE; ADRENAL HYPERPLASIA, CONGENITAL; DNA MUTATIONAL ANALYSIS; ENGLAND; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; NEONATAL SCREENING; POINT MUTATION; RETROSPECTIVE STUDIES;

EID: 84892798164     PISSN: 00039888     EISSN: 14682044     Source Type: Journal    
DOI: 10.1136/archdischild-2013-304473     Document Type: Article

References (37)

1. White PC, Speiser PW. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Endocr Rev 2000;21:245-91.
2. Speiser PW, Azziz R, Baskin LS, et al. Endocrine Society. Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2010;95:4133-60.
3. Seymour CA, Thomason MJ, Chalmers RA, et al. Newborn screening for inborn errors of metabolism: a systematic review. Health Technol Assess 1997;1.
4. UK National Screening Committee. UK NSC Policy database: Congenital Adrenal Hyperplasia (policy currently under review). http://www.screening.nhs. uk/congenitaladrenalhyperplasia (accessed 1 Aug 2013).
5. Therrell BL Jr, Berenbaum SA, Manter-Kapanke V, et al . Results of screening 1.9 million Texas newborns for 21-hydroxylase-deficient congenital adrenal hyperplasia. Pediatrics 1998;101:583 -90.
6. Balsamo A, Cacciari E, Piazzi S, et al. Congenital adrenal hyperplasia: neonatal mass screening compared with clinical diagnosis only in the Emilia-Romagna region of Italy, 1980-1995. Pediatrics 1996;98:362-7.
7. Brosnan PG, Brosnan CA, Kemp SF, et al. Effect of newborn screening for congenital adrenal hyperplasia. Arch Pediatr Adolesc Med 1999;153:1272-8.
8. Thil'en A, Nordenström A, Hagenfeldt L, et al. Benefits of neonatal screening for congenital adrenal hyperplasia (21-hydroxylase deficiency) in Sweden. Pediatrics 1998;101:E11.
9. Van der Kamp HJ, Noordam K, Elvers B, et al. Newborn screening for congenital adrenal hyperplasia in the Netherlands. Pediatrics 2001;108:1320-4.
10. Gleeson HK, Wiley V, Wilcken B, et al. Two-year pilot study of newborn screening for congenital adrenal hyperplasia in New South Wales compared with nationwide case surveillance in Australia. J Paediatr Child Health 2008;44:554-9.
11. Nordenström A, Ahmed S, Jones J, et al. Female preponderance in congenital adrenal hyperplasia due to CYP21 deficiency in England: implications for neonatal screening. Horm Res 2005;63:22-8.
12. Thilén A, Larsson A. Congenital adrenal hyperplasia in Sweden 1969-1986. Prevalence, symptoms and age at diagnosis. Acta Paediatr Scand 1990;79:168-75.
13. Virdi NK, Rayner PH, Rudd BT, et al. Should we screen for congenital adrenal hyperplasia? A review of 117 cases. Arch Dis Child 1987;62:659-62.
14. Kovács J, Votava F, Heinze G, et al. Middle European Workshop on Paediatric Endocrinology-Congenital Adrenal Hyperplasia Study Group. Lessons from 30 years of clinical diagnosis and treatment of congenital adrenal hyperplasia in five middle European countries. J Clin Endocrinol Metab 2001;86:2958-64.
15. Török D, Mühl A, Votava F, et al. Stability of 17α-hydroxyprogesterone in dried blood spots after autoclaving and prolonged storage. Clin Chem 2002;48:370-2.
16. Liivak K, Tobi S, Schlecht H, et al. Incidence of classical 21-hydroxylase deficiency and distribution of CYP21A2 mutations in Estonia. Horm Res 2008;69:227-32.
17. Dolzan V, Sólyom J, Fekete G, et al. Mutational spectrum of steroid 21-hydroxylase and the genotype-phenotype association in Middle European patients with congenital adrenal hyperplasia. Eur J Endocrinol 2005;153:99-106.
18. Wedell A, Thilén A, Ritzén EM, et al. Mutational spectrum of the steroid 21-hydroxylase gene in Sweden: implications for genetic diagnosis and association with disease manifestation. J Clin Endocrinol Metab 1994;78:1145-52.
19. Donaldson MD, Thomas PH, Love JG, et al. Presentation, acute illness, and learning difficulties in salt wasting 21-hydroxylase deficiency. Arch Dis Child 1994;70:214-8.
20. Török D, Eckhardt G, Sólyom J. Twenty years experience in rapid identification of congenital adrenal hyperplasia in Hungary. Eur J Pediatr 2003;162:844-9.
21. Khalid JM, Oerton JM, Dezateux C, et al. Incidence and clinical features of congenital adrenal hyperplasia in Great Britain. Arch Dis Child 2012;97:101-6.
22. Ismail AA, Cawood M, Ufodiama EB, et al. Limitations of 17-hydroxyprogesterone in investigating neonatal hyponatraemia. Ann Clin Biochem 2004;41:245-7.
23. Schwarz E, Liu A, Randall H, et al. Use of steroid profiling by UPLC-MS/MS as a second tier test in newborn screening for congenital adrenal hyperplasia: the Utah experience. Pediatr Res 2009;66:230-5.
24. Lacey JM, Minutti CZ, Magera MJ, et al. Improved specificity of newborn screening for congenital adrenal hyperplasia by second-tier steroid profiling using tandem mass spectrometry. Clin Chem 2004;50:621-5.
25. Minutti CZ, Lacey JM, Magera MJ, et al. Steroid profiling by tandem mass spectrometry improves the positive predictive value of newborn screening for congenital adrenal hyperplasia. J Clin Endocrinol Metab 2004;89:3687-93.
26. Janzen N, Peter M, Sander S, et al. Newborn screening for congenital adrenal hyperplasia: additional steroid profile using liquid chromatography-tandem mass spectrometry. J Clin Endocrinol Metab 2007;92:2581-9.
27. Wong T, Shackleton CH, Covey TR, et al. Identification of the steroids in neonatal plasma that interfere with 17 alpha-hydroxyprogesterone radioimmunoassays. Clin Chem 1992;38:1830-7.
28. Fingerhut R. False positive rate in newborn screening for congenital adrenal hyperplasia (CAH)-ether extraction reveals two distinct reasons for elevated 17alpha-hydroxyprogesterone (17-OHP) values. Steroids 2009;74:662-5.
29. Olgemöller B, Roscher AA, Liebl B, et al . Screening for congenital adrenal hyperplasia: adjustment of 17-hydroxyprogesterone cut-off values to both age and birth weight markedly improves the predictive value. J Clin Endocrinol Metab 2003;88:5790-4.
30. Cavarzere P, Samara-Boustani D, Flechtner I, et al. Transient hyper-17-hydroxyprogesteronemia: a clinical subgroup of patients diagnosed at neonatal screening for congenital adrenal hyperplasia. Eur J Endocrinol 2009;161:285-92.
31. Nordenström A, Wedell A, Hagenfeldt L, et al . Neonatal screening for congenital adrenal hyperplasia: 17-hydroxyprogesterone levels and CYP21 genotypes in preterm infants. Pediatrics 2001;108:E68.
32. Grosse SD, Van Vliet G. How many deaths can be prevented by newborn screening for congenital adrenal hyperplasia? Horm Res 2007;67:284-91.
33. Swerdlow AJ, Higgins CD, Brook CG, et al. Mortality in patients with congenital adrenal hyperplasia: a cohort study. J Pediatr 1998;133:516-20.
34. Murtaza L, Sibert JR, Hughes I, et al. Congenital adrenal hyperplasia-a clinical and genetic survey. Are we detecting male salt-losers? Arch Dis Child 1980;55:622-5.
35. Virdi NK, Green A. Congenital adrenal hyperplasia in Birmingham: a retrospective analysis (1958-1985). J Inherit Metab Dis 1986;9(Suppl 1):152-5.
36. Dumic K, Krnic N, Skrabic V, et al. Classical congenital adrenal hyperplasia due to 21-hydroxylase deficiency in Croatia between 1995 and 2006. Horm Res 2009;72:310-4.
37. Knowles R, Khalid JM, Oerton J, et al. Clinical presentation of older children with congenital adrenal hyperplasia: an important outcome for newborn screening policy. Arch Dis Child 2010;95:A6 -7.